???March is Save Your Vision Month!??? ? Oxidative stress is a significant contributor to #VisionLoss and a part of the natural aging process. However, risk factors such as diet, smoking, and stress can increase your risk. Learn more here:?https://lnkd.in/ezMVzBKs At Nacuity, we’re developing therapies targeting oxidative stress and we hope spreading awareness of the role of oxidative stress in driving blinding eye disease can help prevent these diseases and save vision. #SaveYourVisionMonth Image description: Text on a blue and green background that says, “Save your vision from oxidative stress. Consume antioxidant-rich foods. Avoid smoking and alcohol. Get enough sleep. Reduce stress.” Nacuity Pharmaceuticals logo appears in the top left corner of the graphic and an image of a woman’s eye next to an older woman’s eye appears to the right of the graphic.
Nacuity Pharmaceuticals, Inc.
生物技术研究
Fort Worth，Texas 598 位关注者
Leader in innovative treatments for oxidative stress
关于我们
Nacuity Pharmaceuticals is a clinical-stage leader in innovative treatments for oxidative stress.?The company’s powerful, targeted therapies aim to stop oxidative tissue damage, a driver of many blinding eye diseases and a broad spectrum of serious chronic conditions.?Powered by key backing and technical support from?the world’s leading private funders of retinal disease research, Foundation Fighting Blindness?and?RD Fund, Nacuity is pursuing near-term proof-of-concept data in several of its highly differentiated clinical programs, including retinitis pigmentosa, cataract, and cystinosis, with the potential to be first-of-a-kind therapies and gateways to wider applications.
- 网站
-
https://www.nacuity.com/
Nacuity Pharmaceuticals, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Fort Worth，Texas
- 类型
- 私人持股
- 创立
- 2017
地点
-
主要
获取路线
306 W. 7th St
Ste. 310
US，Texas，Fort Worth，76102
Nacuity Pharmaceuticals, Inc.员工
动态
-
Today, on?Rare?Disease?Day, we stand with the millions of individuals and families affected by?rare?diseases. With over 300 million people worldwide living with a?rare?disease, awareness and action are critical. At Nacuity, we are committed to advancing science and advocacy to bring innovative, targeted treatments to underserved patient communities—especially those impacted by conditions where #OxidativeStress plays a role. Together, we can drive progress, amplify voices, and bring hope to those who need it most. #RareDiseaseDay #RDD #RareDiseaseCare
Imagine the population of the 3rd largest country in the world. ?? Imagine every man, woman, person and child in that country. ?????????? And now imagine every single one of them was living with a rare disease. On #RareDiseaseDay, we aim to highlight the voices of every one of these people and raise awareness about their experiences. Ultimately, giving the rare disease community a platform to share their experiences allows us to generate change and catalyse the process of achieving equity. Download our Infographics: https://lnkd.in/efRbDevB
-
-
Congratulations?to our?partner?Arctic Therapeutics on its recent €26.5 million Series A financing! Arctic Therapeutics is a precision-based drug development and diagnostic testing company using genetic and genealogy information to guide therapeutic development. Arctic is also evaluating our proprietary, GMP-grade formulation of #NACA, NPI-001, to treat the inherited, rare amyloid disease?Hereditary Cystatin C Amyloid Angiopathy?(HCCAA)?in Iceland. Learn more:?https://lnkd.in/eFqqJVju
?? Exciting News from Arctic Therapeutics! ?? We’re thrilled to announce the successful close of a €26.5M oversubscribed Series A financing, backed by a global syndicate of investors including the EIC Fund, Kaldbakur, Sanos Group, Cerebrum DAO, The Lurie Family Foundation, and others. This funding will be used to accelerate the development of our two leading programs: ?? AT-001: An anti-amyloid treatment for rare and common forms of #dementia ?? AT-004: A new-class of treatment for inflammatory skin diseases, including #acne vulgaris, #atopicdermatitis, #rocacea and #psoriasis. We’re also excited to welcome Jeppe Ragnar Andersen Jeppe Ragnar Andersen, CEO of Sanos Group, to our board of directors. His expertise in dermatology and dementia-focused clinical research will be invaluable as we expand our efforts. We appreciate the continued support of?EIC Scaling Club, European Innovation Council and SMEs Executive Agency (EISMEA), Arctica Finance, BBA//Fjeldco, Rannís - The Icelandic Centre for Research, Landspitali University Hospital, NeuroScios GmbH, Children's Hospital of Philadelphia For more information, visit www.arctictherapeutics.com. #HealthcareInnovation #Biotech #DementiaResearch #InflammatorySkinDiseases #SeriesAFunding #ArcticTherapeutics #Fundraising #Innovation, #Alzheimer’s
-
-
We’re grateful to the Usher Syndrome Coalition for highlighting our work to develop treatments for oxidative stress including #RetinitisPigmentosa (RP) in #UsherSyndrome. NPI-001, our investigational formulation of #NACA, recently received Fast Track Designation from the FDA, and a clinical trial is ongoing. Collaboration and awareness are essential in the fight against vision loss, and we deeply appreciate the Coalition’s efforts to connect and empower the Usher syndrome community. Learn more about our science and commitment to innovation:?www.nacuity.com/pipeline/
Last week, we highlighted the promising potential of N-acetylcysteine (NAC), an oral supplement being studied for its ability to combat photoreceptor cell degradation. This therapeutic approach is currently under investigation in the NAC Attack Phase 3 Clinical Trial for Retinitis Pigmentosa (RP). This week, we highlight another promising compound, N-acetylcysteine amide (NACA), a derivative of NAC with a key structural modification: the replacement of NAC's carboxyl (-COOH) group with an amide (-CONH2) group. This chemical change enhances lipophilicity (fat solubility) and membrane permeability, potentially improving drug absorption and effectiveness in reaching retinal cells. Nacuity Pharmaceuticals, Inc. has developed a cGMP-grade (prescription-quality) formulation of NACA, known as NPI-001, as its lead candidate for treating RP. Following successful Phase 1 clinical trials, NPI-001 received both Fast Track Designation and Orphan Drug Designation from the FDA last month, recognizing its potential as a treatment for this rare disease. ?? Read our summary: https://lnkd.in/gXs34tbM ?? See the science: https://lnkd.in/etgtbbHV #UsherSyndrome #RetitinisPigmentosa #RareDisease #ClinicalTrials
-
Connect with the leading experts in?Stargardt?research at the The Carroll Center for the Blind’s #StargardtSummit on February 22, 2025, virtually or in person in Newton MA. Learn more here: https://lnkd.in/emKfrRcu
2025 Stargardt Summit Is Happening Soon! Don’t miss this incredible opportunity to join the #StargardtSummit on Saturday, February 22, 2025! Attend in-person in Newton, MA, or join us virtually from anywhere. Highlights of the day include: ? A powerful keynote by Kenyetta McCurdy Byrd ? Insightful discussions on research, advocacy, and lived experiences ? Exclusive in-person lunch, networking, and breakout sessions Register now at https://lnkd.in/e3AUMBYm and be part of something extraordinary! Special thanks to our sponsor, Alkeus Pharmaceuticals, Inc. and partners, Foundation Fighting Blindness and The Blind Life. #CarrollCenterCommunity #Stargardt #LowVision #SeeWhatsPossible
-
-
February is #RetinitisPigmentosa (RP)?Awareness?Month. An estimated 100,000 people in the U.S. have?RP, a group of inherited retinal diseases causing retinal degeneration and a decline in vision. Learn more about?RP?and access helpful #LowVision resources on the Foundation Fighting Blindness website: https://lnkd.in/dPFADMh
-
-
We’re pleased to announce that the FDA has granted Fast Track Designation to our NPI-001 (N-acetylcysteine amide) tablets, our proprietary investigational therapy for the treatment of patients with #RetinitisPigmentosa (#RP), marking a significant milestone in our mission to bring powerful, targeted treatments to underserved patient communities afflicted by blinding eye diseases. Read more: https://lnkd.in/eDDfHm64 Image Description: Nacuity logo on white background with blue and green geometric design and the text: "Nacuity Pharmaceuticals Granted “U.S. FDA?Fast?Track?Designation?for NPI-001 (N-acetylcysteine amide) Tablets for the Treatment of Retinitis Pigmentosa”
-
-
As 2024 comes to a close, we’re proud to reflect on the significant progress made across our clinical programs targeting #OxidativeStress. Looking ahead to 2025, we’re excited about key upcoming milestones, including the anticipated completion of our SLO-RP study for individuals with #RetinitisPigmentosa associated with #UsherSyndrome. ? None of this would be possible without the dedication of the Nacuity Pharmaceuticals, Inc. team, the invaluable contributions of our #clinicaltrial participants, and the continued support of?all of our partners?including Foundation Fighting Blindness, RD Fund and investors. Together, we’re advancing therapies to improve the lives of underserved patient communities afflicted by blinding eye diseases. Wishing everyone a joyful holiday season and a bright, healthy new year! ? Image Description:?Nacuity?logo on white background with?text that reads: “Thank you & happy new year from?Nacuity?Pharmaceuticals” and a blue, dark blue and green geometric design to the right of the?text.
-
-
Vision loss caused by eye diseases and conditions like Usher syndrome affects every aspect of life. The Usher Syndrome Coalition shares tips to help people with #USH manage their condition and navigate the world.??? ? Image Description: The image features a bright yellow banner at the top with the text "USH LIFE HACK" in bold, black letters. Below the banner, there is a yellow box containing a tip in black text: “We do not have carpeted stairs, so I added individual carpet pads to each stair step inside my house. Doing this lets my feet know I’ve arrived at the top or bottom of the stairs when I no longer feel carpet.” To the right of this text, there's a close-up image of a person’s feet as they walk down a staircase, with visible carpet pads on each step. The Usher Syndrome Coalition logo is displayed at the bottom of the image.
Navigating stairs can be tricky, but a simple life hack like adding carpet pads can make all the difference. Feel the change underfoot and know exactly where you are. Image Description: The image features a bright yellow banner at the top with the text "USH LIFE HACK" in bold, black letters. Below the banner, there is a yellow box containing a tip in black text: “We do not have carpeted stairs, so I added individual carpet pads to each stair step inside my house. Doing this lets my feet know I’ve arrived at the top or bottom of the stairs when I no longer feel carpet.” To the right of this text, there's a close-up image of a person’s feet as they walk down a staircase, with visible carpet pads on each step. The Usher Syndrome Coalition logo is displayed at the bottom of the image. #USHLifeHack #UsherSyndrome #Accessibility #HomeSafety #DeafBlind #RetinitisPigmentosa #DisabilityAwareness #LowVision #OrientationAndMobility
-
-
An?article?recently published in Experimental?Eye?Research demonstrated NPI-001 and NPI-002 (NACA and diNACA) as potent retinal cell antioxidants. These novel retinal antioxident screening tests assess the potential to reduce #oxidativestress in a wide range of retinal diseases. Access the publication here:?https://lnkd.in/gBCCZF-v
-